The Belgian and Swedish developers of a new cancer antibody that targets the placental growth factor (PIGF) are set to receive a €10 million from Roche following the start of a new trial of the drug in patients with colorectal and ovarian cancer.
The Belgian and Swedish developers of a new cancer antibody that targets the placental growth factor (PIGF) are set to receive a €10 million from Roche following the start of a new trial of the drug in patients with colorectal and ovarian cancer.